Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: A pilot study in patients with relapsed/refractory diffuse large B cell lymphoma

MLA

Otto S. Hoekstra, et al. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Jan. 2017. EBSCOhost, https://doi.org/10.1371/journal.pone.0169828.

APA

Otto S. Hoekstra, Yvonne W. S. Jauw, Marc C. Huisman, Josée M. Zijlstra, Daphne de Jong, Guus A.M.S. van Dongen, Danielle J. Vugts, & Sonja Zweegman. (2017). Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: A pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. https://doi.org/10.1371/journal.pone.0169828

Chicago

Otto S. Hoekstra, Yvonne W. S. Jauw, Marc C. Huisman, Josée M. Zijlstra, Daphne de Jong, Guus A.M.S. van Dongen, Danielle J. Vugts, and Sonja Zweegman. 2017. “Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma,” January. doi:10.1371/journal.pone.0169828.